> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Beam Eyes Accelerated Approval for Genetic Disease Therapy
- URL: https://www.fdaweb.com/beam-eyes-accelerated-approval-for-genetic-disease-therapy/
- Published: 2026-03-25T12:00:00.000Z
- Updated: 2026-09-14T13:36:08.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160874

Beam Therapeutics says it will advance its base-editing therapy BEAM-302 into pivotal development to seek accelerated approval for treating Alpha-1 Antitrypsin Deficiency (AATD) after updated Phase 1/2 data showed the drug can durably raise AAT levels above the protective threshold while sharply reducing the disease-causing mutant protein. “AATD is a serious genetic disease that can lead to significant liver disease over an individual’s lifespan along with progressive lung disease in adults,” the company says.

In the ongoing study, patients treated with a single 60 mg dose reached mean steady-state AAT levels of 16.1 µM — comfortably above the 11 µM threshold associated with reduced disease risk — with follow-up extending up to 12 months. The company says all patients in that cohort remained above the protective level.

Across 26 single-dose patients, adverse events were mostly mild to moderate, with no serious events or dose-limiting toxicities reported, according to the company. Transient infusion reactions and asymptomatic liver enzyme elevations were observed, including higher-grade ALT/AST increases in a small multi-dose cohort, but none required intervention.

One datapoint the company highlighted: a patient in the 60 mg cohort mounted a physiological response during a respiratory infection, with AAT levels rising to nearly 30 µM while maintaining predominantly corrected protein — suggesting preserved biological regulation after editing.

Beam is now moving forward with 60 mg as its “optimal biological dose,” arguing the data show near-saturation editing at that level without a clear benefit from higher dosing. It plans to open a global pivotal cohort in the second half of 2026, enrolling roughly 50 additional patients. After discussions with FDA, Beam says it intends to pursue an accelerated approval pathway based on AAT biomarker levels measured over 12 months.